A Pilot Study Of Hycamtin (Topotecan) And Thalomid (Thalidomide) In Patients With Recurrent Malignant Gliomas
- Determine tumor response rate, duration of response, time to disease progression, and
overall survival of patients with recurrent or refractory malignant glioma treated with
topotecan and thalidomide.
- Determine safety and tolerance of this regimen in these patients.
OUTLINE: Patients receive topotecan IV continuously on days 1-21 and oral thalidomide daily
on days 1-28. Treatment repeats every 28 days for a maximum of 6 courses in the absence of
disease progression or unacceptable toxicity.
Patients are followed every 2 months.
PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Pam G. Khosla, MD
Rush University Medical Center
United States: Federal Government
|Rush Cancer Institute at Rush University Medical Center||Chicago, Illinois 60612|